Signaling pathways (p value) | Up regulated genes | Down regulated genes |
---|---|---|
Complement (1 × 10 −6) | C2, C3, C6, C4BPA, CFD, ITGB2, ITGAM, ITGAX | C7 |
B cell development (6 × 10 −6) | HLA-DRA, HLA-DRB5, HLA-DQB1, IL7, IL7R, PTPRC, SPN | – |
CD28 signaling in Th cells (1 × 10 −5) | HLA-DRA, HLA-DRB5, HLA-DQB1, CD247, CD3E, CD3G, GRAP2, PAK1, PTPRC, VAV1 | Calm1, FOS, PIK3C2G, PIK3R3 |
ICOs/ICOSL signaling in Th cells (1.3 × 10 −5) | CD247, CD3E, CD3G, GRAP2, HLA-DQB1, HLA-DRA, HLA-DRB5, PTPRC, VAV1 | Calm1, CAMK2D, PIK3C2G, PIK3R3 |
Nur 77 signaling in T cells (5 × 10 −5) | CD247, CD3G, HLA-DRA, HLA-DRB5, HLA-DQB1, CD3E | Calm1, CASP3 |
Agranulocyte adhesion and diapedesis (0.0001) | ACTC1, AOC3, CCL4, CCL9, EZR, IL18, ITGB2, MYH3 | CCL20, CD34, CLDN5, CXCL2, CXCR4, ICAM2, MMP27 |
Granulocyte adhesion and diapedesis (0.00013) | CCL4, CCL9, EZR, IL18, ITGAM, ITGB2 | CCL20, CLDN5, CXCL2, CXCR4, ICAM2, IL1R2, MMP27 |
Cross talk between DCs and NK cells (0.001) | ACTG2, HLA-DRA, HLA-DRB5, IL18 | IL6, MIBC, FSCN1, CAMK2D, ACTC1, TNFSF10 |
Antigen presentation pathway (0.001) | CIITA, CD74, HLA-DRA, HLA-DRB5 | – |
Acute phase response signaling (0.001) | AGT, C2, C3, C4BPA, IL18, KLKB1, RBP4, SERPINA3 | FOS, IL6, PIK3R3, VWF |
Role of hypercytokinemia/hyperchemokinemia in the pathogenesis (0.003162) | CCL4, IL18 | IL6 |
TREM1 signaling (0.0631, NS) | CIITA, IL18, ITGAX, TLR11 | IL6 |
IL-10 signaling (0.0631, NS) | IL18, IL10RA | FOS, IL6, IL1R2 |
Differential regulation of cytokine production in MΦ and Th cell (0.1, NS) | CCL4 | IL6 |
IL-6 signaling (0.1259, NS) | IL18 | IL6, FOS, IL1R2, PIK3C2G, PIK3R3 |
HMGB1 signaling (0.1259, NS) | IL18 | IL6, FOS, PIK3C2G, PIK3R3, RHOJ |
Inhibition of matrix metalloproteinase (0.2512, NS) | THBS2 | MMP27 |
IL-17 signaling in fibroblast (0.2512, NS) | IL6, FOS | |
MIF regulation of innate immunity (0.3162, NS) | CD74 | FOS |
MIF-mediated glucocortical regulation (0.5012, NS) | CD74 | – |
Toll-like receptor signaling (1.0, NS) | IL18 | FOS |